Stock Fundamentals

Divi’s Labs: regulatory woes

Dhuraivel Gunasekaran | Updated on January 15, 2018 Published on March 26, 2017

2503Divis_c_col



The stock of Divi's Laboratories fell about 20 per cent last Tuesday after the company informed exchanges that its Unit II facility at Vishakhapatnam, Andhra Pradesh, had received an import alert from the US regulator Food and Drug Administration (USFDA). The facility accounts for about 70 per cent of the US product revenue. The US business accounts for about 32 per cent of the company’s overall revenue.

This development is subsequent to the form 483 issued by the US FDA to the facility in late 2016. This form had five observations for deviation from compliance requirements. The import alert now is a major setback for the company with existing capacity constraints and the delay in acquisition of land in Kakinada for greenfield expansion. A silver lining is that 10 active pharmaceutical ingredients (APIs) are exempted from the import alert.

Given the significant revenue contribution from the facility, an early resolution of the issues is imperative for the company.

Published on March 26, 2017

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Sincerely,

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.